

- Alcohol withdrawal syndrome
clinical features of, 2727
delirium in, 166, 169
hypokalemia in, 64e-7, 305
treatment of, 2727-2728
- Aldehyde dehydrogenase (ALDH), 2058, 2726
- ALDEN (Algorithm of Drug Causality for Epidermal Necrolysis), 384
- Aldesleukin. *See* Interleukin-2 (IL-2) therapy
- Aldolase deficiency, 654t
- Aldosterone
action of, 296, 304-305, 306, 332e-5f, 332e-9
excess of. *See* Glucocorticoid-remediable aldosteronism (GRA);
Hyperaldosteronism
in potassium regulation, 304-305
ratio to plasma renin activity, 1618
reference values for, 2757t
in shock, 1745-1746
in sodium regulation, 332e-11
synthesis of, 2309f, 2313, 2314f
- Aldosterone antagonists, 1623, 1624t
- Aldosterone escape, 332e-11
- Aldosterone-renin-ratio (ARR), 1618, 2319, 2320t
- Aldosterone synthase, 434
- Alemtuzumab
action and targets of, 102e-5t, 103e-21t, 2670
adverse effects of, 488, 1798, 2670
for CLL, 102e-5t, 703
for graft-versus-host disease prevention, 921
for hypereosinophilic syndromes, 135e-8
for immunosuppression, 1828
for MS, 2670
for myelodysplasia, 671
- Alendronate
adverse effects of, 2499
for osteoporosis management/prevention, 2383, 2499, 2500f, 2504
for Paget's disease of bone, 426e-3, 426e-3t
- Alenquer virus, 1309t
- Alexander technique, 14e-1t
- Alexia, 177, 177t, 178-179
- Alfentanil, 246e-3t, 1741
- Alfimeprase, 760
- ALG. *See* Antilymphocyte globulin (ALG)
- Alginic acid, 263
- Algorithm of Drug Causality for Epidermal Necrolysis (ALDEN), 384
- ALI. *See* Acute lung injury (ALI)
- Alien hand (limb) syndrome, 179, 2605
- Alipogene tiparvovec, 2440
- Aliskiren, 1512, 1623, 1624t, 1625
- Alkaline phosphatase (ALP)
in hypophosphatasia, 426e-5
in jaundiced patient, 283
in liver abscess, 850
in liver function evaluation, 1996f, 1997, 1998t
in Paget's disease of bone, 426e-1, 426e-3
tissue nonspecific, 426e-5
- Alkali therapy, 320, 321. *See also* Bicarbonate therapy
- Alkaptonuria, 434e-2t, 434e-4-5
- ALK gene mutations, 507t, 508, 509f, 521
- Alkylating agents, 103e-8, 103e-9t. *See also* specific drugs
action of, 103e-8
adverse effects of, 103e-8, 103e-9t
anemia, 398, 664t
in essential thrombocytosis, 678
hair loss, 380
infertility, 623
late, 620t, 621, 670, 678
pulmonary, 621
seizures, 2547t
for breast cancer, 530
carcinogenicity of, 477t, 678
- ALL. *See* Acute lymphoid leukemia (ALL)
- Allele(s), 435
association of, 442
exclusion of, 439
frequency of, 442
heterogeneity of, 433f, 435, 436t
segregation of, 437, 438
types of, 435
- Allele-sharing methods, 442t
- Allelic exclusion, 372e-20, 710
- Allelic loss, 538
- Allen's test, 1445
- Allergic angitis and granulomatosis. *See* Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
- Allergic bronchopulmonary aspergillosis (ABPA)
bronchiectasis in, 1695
clinical features of, 1346t, 1347
in cystic fibrosis, 1699
diagnosis of, 1681, 1686
etiology of, 1686
genetic considerations in, 1346
treatment of, 1349t, 1681, 1686
- Allergic conjunctivitis, 199
- Allergic contact dermatitis. *See* Contact dermatitis, allergic
- Allergic fungal sinusitis, 228
- Allergic granulomatosis, 366
- Allergic interstitial nephritis. *See* Acute interstitial nephritis (AIN), allergic
- Allergic reactions. *See* Hypersensitivity reactions
- Allergic rhinitis, 2121, 2123f
- Allergic vasculitis, 422
- Allergy, 2114
in asthma, 1669-1670, 1671
atopic, 2114
eosinophils in, 422
pathophysiology of, 2114-2116, 2115f
- Alligator bite-wound, 167e-1
- Alloantibodies, 138e-1-2, 138e-1t
- Alloantibody screen, 138e-2
- Allodynia, 87, 158, 2643
- Alloimmunization, 138e-1, 138e-2, 138e-5
- Allopurinol
adverse effects of
cutaneous, 353, 361, 2235
fever, 138, 2705
genetic considerations in, 378
hypersensitivity, 382. *See also* Drug-induced hypersensitivity syndrome (DIHS)
serious, 2235
SJS or TEN, 383. *See also* Stevens-Johnson syndrome (SJS); Toxic epidermal necrolysis (TEN)
vasculitis, 382, 2193, 2218t
drug interactions of, 42, 42t, 2234-2235
azathioprine, 103e-10t, 2705
6-mercaptopurine, 103e-10t
theophylline, 1677
for gout, 2234-2235
for hyperuricemia in myeloproliferative diseases, 674, 676
pyrimidine metabolism and, 431e-6
for uric acid nephrolithiasis, 431e-5, 1871
for uric acid nephropathy, 431e-5
- Alloreactivity, 373e-5
- Allotaxis, 186
- Allotypes, of immunoglobulins, 710
- All-trans-retinoic acid (ATRA). *See also* Retinoic acid
action and targets of, 102e-5t, 102e-7, 103e-16, 103e-17t
for acute promyelocytic leukemia, 102e-5t, 102e-7, 103e-17t, 686
adverse effects of, 103e-16, 103e-17t, 366
- Allylamines, 350
- Almotriptan, 2591, 2592t, 2593t
- Alogliptin, 291e-7, 2414t
- Alopecia, 354
androgenetic, 354, 355t
androgenic, 331
definition of, 340t
drug-induced, 103e-25, 354, 379-380
etiology of, 354-355, 355t
nonscarring, 354, 355t
scarring, 354, 355t
in tinea capitis, 350
traumatic, 354, 355t
treatment of, 355t
- Alopecia areata, 76e-3f, 354, 355t
- Alosetron, 272, 566, 1970, 1970t
- ALP. *See* Alkaline phosphatase (ALP)
- α_1 -adrenergic agonists, 473e-8t
- α_2 -adrenergic agonists, 54, 200, 468e-3, 473e-9t
- α -adrenergic antagonists
adverse effects of, 146, 241, 253t
aldosterone-renin ratio effects of, 2320t
drug interactions of, 587
for hypertension, 1624, 1624t
for lower urinary tract symptoms, 7e-4, 587
overdosage/poisoning with, 473e-3, 473e-9t
- α -adrenergic receptors, 1613, 1745
- α chains, 2506
- Alpha coma, 1775
- Alpha diversity, 86e-1t, 86e-4-5
- α fetoprotein (AFP)
in carcinoma of unknown primary, 120e-1, 120e-2t
ectopic production of, 608
in hepatocellular carcinoma, 546
in testicular cancer, 588
as tumor marker, 473t
- Alpha-granules, 275, 741
- α heavy chain disease (Seligman's disease), 537, 718-719
- α -hemolytic streptococci, 963, 964t, 971. *See also* *Streptococcus pneumoniae*
- α -lipoic acid, 216, 239, 2348
- α motor neurons, 155f
- Alpha (α) radiation, 263e-1
- Alpharadin (radium-223 chloride), 119e-4, 586, 587
- α -synuclein, 453e-6, 2612
- Alphaviruses, 91e-1t, 1306t
- Alphavirus (togavirus) infections
Barmah Forest virus infection, 837, 1313
chikungunya virus infection. *See* Chikungunya virus infection
clinical syndromes of, 1306t, 1313
Eastern equine encephalitis, 1316
geographic distribution of, 1311-1312t
Ross River virus infection (epidemic polyarthritis), 837, 1313
Sindbis virus infection, 1314
Venezuelan equine encephalitis, 1317
Western equine encephalitis, 1317
Zika virus infection, 1314
- Alport's syndrome, 2513
clinical features of, 220, 1836, 1847
diagnosis of, 1847, 2514
forms of, 2513-2514
genetic considerations in, 1832, 1847, 2514
hearing loss in, 220, 222t
incidence of, 2514
renal biopsy in, 62e-8f, 1847
treatment of, 1847
- Alprazolam
adverse effects of, 64
for anxiety disorders, 2711t
for depression, 64
drug interactions of, 246e-3t
overdosage/poisoning with, 473e-10t
for panic disorder, 2709
pharmacology of, 2711t
- Alprostadil, 329
- ALPS (autoimmune lymphoproliferative syndrome), 2112
- ALS. *See* Amyotrophic lateral sclerosis (ALS)
- Alsin gene, 2633, 2634t
- ALS/parkinsonian/dementia complex of Guam, 2608
- ALT. *See* Alanine aminotransferase (ALT)
- Alteplase (rtPA)
action of, 759
for acute limb ischemia, 1646
catheter-directed therapy with, 1636
contraindications to, 1605
domain structure of, 759, 759f
indications for, 759
for ischemic stroke, 2561-2562, 2562t
for myocardial infarction, 1605
for occluded catheter, 98e-7
for pulmonary embolism, 1636